Funding profile · Kinase drug discovery

Harmonic Discovery

A 2021 New York biotech that announced $8 million of seed capital in September 2022 and has announced no round since. No Form D has ever been filed under its name, and no federal grant appears in the award databases.

$8.0MSeed announced Sep 8, 2022, company-stated and confirmed by its law firm
$8.5MTotal raised as stated by Hub71, Sep 2, 2025
0Form D notices on file with the SEC under any Harmonic Discovery name
$0Federal grant dollars found in NIH RePORTER and NSF award records

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2021 Y Combinator, Summer 2021 Not disclosed Y Combinator YC data
Before Sep 2022 Pre-seed Not disclosed Led by Innovation Endeavors, with Fifty Years Investor essay
Sep 8, 2022 Seed, announced at launch $8,000,000 Innovation Endeavors (lead), Fifty Years, Y Combinator, Boom Capital, Caffeinated Capital, angels including Ethan Perlstein and Harry Glorikian Company release
Jan 30, 2024 Total restated in a licensing release $8 million to date Innovation Endeavors, Fifty Years, Y Combinator and other select investment firms Company release
Apr 1, 2024 Total restated in a partner release $8 million to date Same list Partner release
Sep 2, 2025 Total restated by an accelerator $8.5 million Not itemised Differs from company figure
2021 to 2026 Federal grants None found NIH, NSF Public record

What the filings show

Harmonic Discovery Inc. · no Form D located · searched Sep 22, 2026

Company search
EDGAR company lookup for harmonic discovery, form type D: no matching companies
Adjacent names
17 registrants match the word harmonic, among them Harmonic Bionics, Harmonic Inc., Harmonic Security and two Harmonic SPVs. None is this company.
Full text search
Three hits for the phrase, all in 2018 registration statements by an unrelated filer
Offered
Not on record
Sold
Not on record
Investors
Not on record
Filing
SEC EDGAR, no CIK assigned to this issuer

Federal award records · queried Sep 22, 2026

NIH RePORTER
0 projects for the organisation name, 0 for the chief executive as principal investigator
NSF awards
0 awards to this company. Name matches in the records pull resolve to Harmonic Bionics, Discovery Simulations and Sanford Burnham Prebys.
SBIR or STTR
None located
Implication
100 percent of identified capital is equity

Reading the filings

  1. There is no filing arithmetic to do.Every other page of this kind divides dollars sold by investor count. Here there is nothing to divide. A company can raise under Section 4(a)(2) rather than Regulation D and owe the SEC no notice, so silence is not evidence that money did not move. It does mean the only numbers available are the ones the company chose to publish.
  2. The two published totals disagree by $500,000.Company releases in 2022, January 2024 and April 2024 all say $8 million. Hub71, announcing Harmonic Discovery in its seventeenth cohort on September 2, 2025, says USD 8.5 million, or AED 31.2 million. That is a 6.25 percent gap. No filing settles it, and neither figure has been amended.
  3. Four years of runway on one announced round.The seed was announced in September 2022. As of September 2026 no further round has been announced. Y Combinator lists a team of 8. A company that size at a shared incubator bench can stretch $8 million a long way, but four years is long, and in a late 2025 interview the company said it would open a round early the following year.
  4. The lead asset was bought, not bred.HD-10019 came in under an exclusive licence from BioVentures at the University of Arkansas for Medical Sciences and from UCSF in January 2024. Terms were not disclosed, which means any upfront payment, milestone ladder or royalty stack sits outside every public number on this page.
  5. None of the capital is non-dilutive.Companies at this stage of drug discovery often carry an SBIR or an NIH grant alongside venture money. This one carries none that the award databases record, so equity has paid for all of it.
  6. The newest capital signal is geographic, not financial.The only 2025 disclosure of substance is an Abu Dhabi accelerator placement and a stated intention to run preclinical work there. That is a cost and access decision rather than a financing event, and it is the most recent thing on the record.

Commercial signals

Signal Detail Source type
Stage Preclinical. No registered clinical trial. IND-enabling studies for HD-10019 were expected to start in late 2024; no confirmation found. Public record
Revenue None disclosed. No product, no service pricing, no named customer. Not found
Partnerships Turbine, announced Apr 1, 2024, on the dark kinase NEK1. Financial terms not disclosed. No milestone reported since. Partner-stated
In-licensing HD-10019 from BioVentures and UCSF, Jan 30, 2024. Terms not disclosed. Company-stated
Technical validation Nature Communications paper, Aug 2024: 347 compound kinase pairs profiled, 40 percent hit rate, 78 percent negative predictive value. Public record
Shop window BIO-Europe 2024 startup spotlight finalist; BIO convention exhibitor, June 2025; Hub71 cohort 17, Sep 2025. Independent

What to watch

  • A first Form D. It would be due within 15 days of the first sale of any Regulation D round.
  • Whether the next raise is priced venture equity or regional strategic money from the Gulf.
  • Any disclosure of the BioVentures and UCSF licence economics.
  • A first grant. An NIH or Business Finland award would show up in public records within a quarter of being made.
  • A registered phase one trial, which the company said in late 2025 was 18 to 24 months away.

The Harmonic Discovery story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Talus Bio: Shared investor: Boom Capital. A Seattle company that strips a living human cell down to the proteins still gripping DNA, measures all of them at once by mass spectrometry, and uses the result to hunt
  • Catena Biosciences: Shared investor: Caffeinated Capital. A UC Berkeley spinout that uses an engineered tyrosinase to weld two proteins together through their native amino acids, now aimed at antibody drug conjugates carrying
  • Dorian Therapeutics: Shared investor: Boom Capital. A Stanford spinout that built small molecule blockers of USP16, the enzyme that strips a silencing mark off histone H2A, and pointed them at the arthritic knee
  • Known Medicine: Shared investor: Caffeinated Capital. A Salt Lake City company that grew hundreds of micro-tumors from one patient sample and dosed each, to tell an oncologist what would work

Sources

  1. Public recordEDGAR company search, form type D, for Harmonic Discovery and for HarmonicSEC · queried Sep 22, 2026
  2. Public recordEDGAR full text search for the phrase Harmonic DiscoverySEC · queried Sep 22, 2026
  3. Public recordNIH RePORTER project search by organisation and by principal investigatorNIH · queried Sep 22, 2026
  4. Public recordLeveraging multiple data types for improved compound-kinase bioactivity predictionNature Communications · Aug 31, 2024
  5. IndependentHub71 welcomes record AI startups in latest cohortHub71 press release · Sep 2, 2025
  6. IndependentFirm advises Harmonic Discovery on launch, $8 million seed roundWilson Sonsini Goodrich & Rosati · Sep 8, 2022
  7. InvestorHarmonic Discovery, describing a pre-seed and a series seedFifty Years · Sep 16, 2022
  8. InterviewRevolutionizing sickle cell treatment: the journey of Harmonic DiscoveryFINTECH.TV · 2025
  9. CompanyHarmonic Discovery launches with $8 million in seedPR Newswire · Sep 8, 2022
  10. CompanyLicensing agreement with BioVentures and UCSF for the FLT3 mutated AML programPR Newswire · Jan 30, 2024
  11. PartnerTurbine and Harmonic Discovery collaboration on NEK1Turbine · Apr 1, 2024
  12. CompanyHarmonic Discovery Y Combinator company page, Summer 2021, team size 8Y Combinator · accessed Sep 2026

Compiled from SEC, NIH, NSF and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; the absence of one does not establish that no securities were sold, because issuers may rely on other exemptions. Healthcare Venture Capital Fund holds no position in Harmonic Discovery. This page is not an offer to sell or a recommendation to buy any security.